Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness IM8, a New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com CHARLOTTE, N.C., Dec. 19, 2024 /PRNewswire/ -- Prenetics'...

X Financial Announces US$48.7 Million Share Repurchase from Major Shareholder

X Financial Announces US$48.7 Million Share Repurchase from Major Shareholder

SHENZHEN, China, Dec. 19, 2024 /PRNewswire/ -- X Financial (NYSE: XYF) (the "Company" or "we"), a leading online personal finance company in China, today announced that it has entered into a repurchase agreement with a major shareholder on December...

Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete

Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete

MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has completed the installation of two new cyclotrons at Telix Manufacturing...

Trip.com Group Unites Partners to Drive Growth and Explore New Opportunities at the 2024 Global Partner Summit

Trip.com Group Unites Partners to Drive Growth and Explore New Opportunities at the 2024 Global Partner Summit

Travel industry leaders gathered in Abu Dhabi for Trip.com Group's Global Partner Summit, celebrating a year of strong growth marked by a 70% year-on-year increase in Asia-Pacific bookings. Trip.com Group announces a strategic partnership with...

Jones Day names 37 new partners

Jones Day names 37 new partners

WASHINGTON, Dec. 19, 2024 /PRNewswire/ -- The global law firm Jones Day announces that the 37 lawyers listed below will be admitted to the Firm's partnership effective January 1, 2025. Jones Day names 37 new partners (presented in alphabetical...

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Pharus Diagnostics LLC. (PharusDx), an innovator in non-invasive diagnostic tests, today announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability...

Shengfeng Development Limited Announces Completion of the Ningde Shengfeng Smart Logistics Center, Primarily Servicing CATL

Shengfeng Development Limited Announces Completion of the Ningde Shengfeng Smart Logistics Center, Primarily Servicing CATL

FUZHOU, China, Dec. 18, 2024 /PRNewswire/ -- Shengfeng Development Limited ("Shengfeng" or the "Company") (NASDAQ: SFWL), a contract logistics company in China providing customers with integrated logistics solutions, announced today the completion...

Boryung Announces Winners of the 3rd Humans In Space Challenge

Boryung Announces Winners of the 3rd Humans In Space Challenge

Paving the Way as a Global Leader in Space Healthcare - Introducing of a new funding model to support space experiments and strengthen research in space healthcare - Hosted the final round of the Humans In Space Challenge at the 75th International...

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

In a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg, subcutaneous ( SQ ) , once every four weeks plus semaglutide, 30 nmol/kg, SQ, once daily) , demonstrated superior weight loss compared to...

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)

BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the Investigational...

  • 1
  • ...
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • ...
  • 152
  • menu
    menu